Skip to content Skip to footer
Subscribe Now
NEWS

Novartis to Acquire Myricx Bio for ~$1.5B

Shots: Novartis has entered into an agreement to acquire Myricx Bio, strengthening Novartis’ oncology pipeline & advancing next-generation targeted drug conjugates with novel payload mechanisms Myricx is developing ADCs, using NMT inhibitor (NMTi) payloads designed to disrupt key cancer cell processes, with preclinical data showing broad activity across solid tumors, incl. TOPO-1-resistant models As per…
July 6, 2026

Read more

NEWS

CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal

Shots: CSPC & AstraZeneca have entered into a strategic collaboration, option & license agreement to leverage CSPC’s siRNA discovery & extrahepatic targeted delivery platforms to develop novel small nucleic acid therapeutics CSPC & AstraZeneca will jointly discover & develop preclinical candidates for two renal disease targets, with AstraZeneca holding options for global/ex-China rights to each…
July 3, 2026

Read more

NEWS

Median Technologies Receives CE Mark for eyonis LCS to Detect and Diagnose Lung Cancer

Shots: Median Technologies has received CE Mark for eyonis Lung Cancer Screening (LCS) to detect & diagnose lung cancer In testing eyonis LCS has showed 93.3% sensitivity & 92.4% specificity, with 68% reduction of False Positives & 66% reduction of False Negatives, minimizing unnecessary follow-ups eyonis Lung Cancer Screening is an AI-powered computer-aided detection & diagnosis…
July 3, 2026

Read more

NEWS

AlzeCure Partners with QuantumCell for NeuroRestore ACD856 in a Deal Worth up to $2.2B

Shots: AlzeCure Pharma has entered into an out-licensing & collaboration agreement with QuantumCell for global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, incl. ACD856 AlzeCure will receive $12M upfront, incl. a $5M investment, & is eligible for development & commercial milestones exceeding $2.2B (excl. royalties), plus tiered single to low double-digit royalties NeuroRestore ACD856 is a…
July 3, 2026

Read more

INSIGHTS+

Q2 in Review: Pharma’s Dealmaking Surge, a Wave of FDA Approvals, and AI’s Deepening Footprint 

A PharmaShots Quarterly Analysis  Q2 was one of the most active quarters in recent memory for the pharmaceutical and biotech industry. Big Pharma leaned hard into M&A and licensing to refill pipelines, the FDA cleared a broad slate of new therapies, and AI-native partnerships continued to reshape how drugs get discovered. Below, we break down the quarter…
July 2, 2026

Read more

NEWS

Inocras and AimedBio Collaborate on Precision Oncology and ADC Development

Shots: Inocras and AimedBio have partnered to integrate Inocras’ whole-genome sequencing (WGS) platform into AimedBio’s ADC clinical programs, alongside AimedBio’s strategic equity investment in Inocras As per the deal, AimedBio will use Inocras’ WGS, cancer intelligence platform, & multi-omics analyses across its ADC trials to enable biomarker discovery, patient selection, and novel target identification The…
July 2, 2026

Read more

Load more